|
Investigation of telomerase inhibition effect on apoptosis of myeloma cell line U266
|
Z. Ameri   , S. Ghiasi , A.R. Farsinejad , M. Ehsan , S. Aghajani , N. Pur Yazdan Panah , Sh. Kazemzadeh , A. Fatemi |
|
|
| Keywords: Key words: Apoptosis, Multiple Myeloma, Telomerase |
|
|
Full-Text [PDF 913 kb]
(1958 Downloads)
| Abstract (HTML) (4529 Views)
|
Type of Study: Research |
Subject:
Hematology and Oncology
Published: 2017/09/11
|
|
|
|
|
|
|
Full-Text: (2323 Views) |
References:
- Urashima M, Ogata A, Chauhan D, Hatziyanni M, Vidriales M, Dedera D, et al. Transforming growth factor-beta1: differential effects on multiple myeloma versus normal B cells. Blood 1996; 87(5): 1928-38.
- Teoh G, Anderson KC. Interaction of tumor and host cells with adhesion and extracellular matrix molecules in the development of multiple myeloma. Hematol Oncol Clin North Am 1997; 11(1): 27-42.
- Kwan Tat S, Padrines M, Théoleyre S, Heymann D, Fortun Y. IL-6, RANKL, TNF-alpha/IL-1: interrelations in bone resorption pathophysiology. Cytokine Growth Factor Rev 2004; 15(1): 49-60.
- Olaussen KA, Dubrana K, Domont J, Spano JP, Sabatier L, Soria JC. Telomeres and telomerase as targets for anticancer drug development. Crit Rev Oncol Hematol 2006; 57(3): 191-214.
- Blum B, Moseley J, Miller L, Richelsoph K, Haggard W. Measurement of bone morphogenetic proteins and other growth factors in demineralized bone matrix. Orthopedics 2004; 27(1 Suppl): S161-5.
- Reagan MR, Liaw L, Rosen CJ, Ghobrial IM. Dynamic interplay between bone and multiple myeloma: emerging roles of the osteoblast. Bone 2015; 75: 161-9.
- Bataille R, Chappard D, Alexandre C, Dessauw P, Sany J. Importance of quantitative histology of bone changes in monoclonal gammopathy. Br J Cancer 1986; 53(6): 805-10.
- Shammas MA, Reis RJS, Akiyama M, Koley H, Chauhan D, Hideshima T, et al. Telomerase inhibition and cell growth arrest by G-quadruplex interactive agent in multiple myeloma. Mol Cancer Ther 2003; 2(9): 825-33.
- Strahl C, Blackburn EH. Effects of reverse transcriptase inhibitors on telomere length and telomerase activity in two immortalized human cell lines. Mol Cell Biol 1996; 16(1): 53-65.
- Reuter S, Prasad S, Phromnoi K, Kannappan R, Yadav VR, Aggarwal BB. Embelin suppresses osteoclastogenesis induced by receptor activator of NF-κB ligand and tumor cells in vitro through inhibition of the NF-κB cell signaling pathway. Mol Cancer Res 2010; 8(10): 1425-36.
- Low KC, Tergaonkar V. Telomerase: central regulator of all of the hallmarks of cancer. Trends Biochem Sci 2013; 38(9): 426-34.
- Seimiya H, Oh-hara T, Suzuki T, Naasani I, Shimazaki T, Tsuchiya K, et al. Telomere Shortening and Growth Inhibition of Human Cancer Cells by Novel Synthetic Telomerase Inhibitors MST-312,
MST-295, and MST-1991. Mol Cancer Ther 2002; 1(9): 657-65 .
- Serrano D, Bleau AM, Fernandez-Garcia I, Fernandez-Marcelo T, Iniesta P, Ortiz-de-Solorzano C, et al. Inhibition of telomerase activity preferentially targets aldehyde dehydrogenase-positive cancer stem-like cells in lung cancer. Mol Cancer 2011; 10(1): 96.
- Weiss C, Uziel O, Wolach O, Nordenberg J, Beery E, Bulvick S, et al. Differential downregulation of telomerase activity by bortezomib in multiple myeloma cells-multiple regulatory pathways in vitro and ex vivo. Br J Cancer 2012; 107(11): 1844-52.
- Zhihua Z, Miaomiao S, Jianping Y, Kuisheng C. Research for the influence of telomerase inhibitors on myeloma cell and therapy. Pak J Pharm Sci 2014; 27(5 Suppl): 1641-4.
- Fatemi A, Safa M, Kazemi A. MST-312 induces G2/M cell cycle arrest and apoptosis in APL cells through inhibition of telomerase activity and suppression of NF-κB pathway. Tumour Biol 2015; 36(11): 8425-37.
- Shiratsuchi M, Muta K, Abe Y, Motomura S, Taguchi F, Takatsuki H, et al. Clinical significance of telomerase activity in multiple myeloma. Cancer 2002; 94(8): 2232-8.
- Wang ES, Wu K, Chin AC, Chen-Kiang S, Pongracz K, Gryaznov S, et al. Telomerase inhibition with an oligonucleotide telomerase template antagonist: in vitro and in vivo studies in multiple myeloma and lymphoma. Blood 2004; 103(1): 258-66.
- Klein B, Zhang XG, Lu ZY, Bataille R.. Interleukin-6 in human multiple myeloma. Blood 1995; 85(4): 863-72.
- Wong VC, Morrison A, Tabori U, Hawkins CE. Telomerase inhibition as a novel therapy for pediatric ependymoma. Brain Pathol 2010; 20(4): 780-6.
- Chung SS, Oliva B, Dwabe S, Vadgama JV. Combination treatment with flavonoid morin and telomerase inhibitor MST-312 reduces cancer stem cell traits by targeting STAT3 and telomerase. Int J Oncol 2016; 49(2): 487-98.
- Wang Y, Sun C, Mao A, Zhang X, Zhou X, Wang Z, et al. Radiosensitization to X-ray radiation by telomerase inhibitor MST-312 in human hepatoma HepG2 cells. Life Sci 2015; 123: 43-50.
- Gurung RL, Lim SN, Low GKM, Hande MP. MST-312 alters telomere dynamics, gene expression profiles and growth in human breast cancer cells. J Nutrigenet Nutrigenomics 2014; 7(4-6): 283-98.
|
Sci J Iran Blood Transfus Organ 2017; 14(3): 204-216
|
Investigation of telomerase inhibition effect on
apoptosis of myeloma cell line U266
Ameri Z.1, Ghiasi S.1, Farsinejad A.R.1, Ehsan M.1, Aghajani S.1, Pur Yazdan Panah N.1,
Kazemzadeh Sh.2, Fatemi A.1
1Faculty of Allied Medical Sciences, Kerman University of Medical Sciences, Kerman, Iran
2Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran
Abstract
Background and Objectives
Telomerase-targeted therapy for cancer has received great attention because telomerase is expressed in almost all cancer cells but is inactive in most normal somatic cells. This study aimed to investigate the effects of telomerase inhibitor MST-312, a chemically modified derivative of epigallocatechin gallate (EGCG), on apoptosis of myeloma cell line U266.
Materials and Methods
In an Experimental study, U266 cells were treated with different concentrations of MST-312 at different times; then, cell viability by trypan blue exclusion assay, cell metabolic activity by MTT assay, and cell apoptosis by Annexin V Apoptosis Detection Kit were measured. To further investigate apoptosis, BAX and BCL2 gene expression of the treated cells was investigated by the quantitative Real-Time PCR.
Results
MST-312 exerted a dose-dependent short-term cytotoxic effect on myeloma cells. Over 50% decrease in the viability of treated cells was seen in 8 μM concentration of MST-312 within 48 h. The cytotoxic effect of MST-312 was concentration-dependent, with approximately 25, 46, and 62% reduction in metabolic activity after 48 h exposure to 2, 4, and 8 μM of MST-312, respectively. Gene expression analysis showed downregulation of antiapoptotic gene Bcl-2 and upregulation of apoptopic gene BAX.
Conclusions
Inhibition of telomerase activity by MST-312 represents a novel treatment strategy for Multiple Myeloma cancer.
Key words: Apoptosis, Multiple Myeloma, Telomerase
Received: 20 May 2017
Accepted: 11 Jul 2017
Correspondence: Fatemi A., PhD of Hematology & Blood Banking. Assistant Professor of Faculty of Allied Medical Sciences, Kerman University of Medical Sciences.
Postal Code: 7619794435, Kerman, Iran. Tel: (+9834) 32112007; Fax: (+9834) 31325375
E-mail:
ahmad.fatemi2@gmail.com
|
|
| Send email to the article author |
|
|
|
| Add your comments about this article |
|
|
|
|
Ameri Z, Ghiasi S, Farsinejad A, Ehsan M, Aghajani S, Pur Yazdan Panah N, et al . Investigation of telomerase inhibition effect on apoptosis of myeloma cell line U266. Sci J Iran Blood Transfus Organ 2017; 14 (3) :204-216 URL: http://bloodjournal.ir/article-1-1121-en.html
|
.jpg)
.png)
